We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Teva Pharmaceutical Industries Ltd | NYSE:TEVA | NYSE | Depository Receipt |
Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.02 | 0.14% | 14.00 | 14.13 | 13.81 | 13.92 | 8,987,446 | 01:00:00 |
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will host a live audio webcast at the Morgan Stanley Global Healthcare Conference in New York, NY.
What: Teva Presentation at the Morgan Stanley Global Healthcare Conference in New York, NY.
Who: Michael McClellan, Chief Financial Officer
When: Friday, September 14, 2018 at 9:20am (ET)
Where: Teva's Investor Relations website at ir.tevapharm.com. The webcast can also be accessed through the following URL: https://cc.talkpoint.com/morg007/091218a_as/?entity=140_5NHE0JF
How: Register for the event approximately 10 minutes before the scheduled start time. An archive of the webcast will be available on Teva's Investor Relations website.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global leader in generic medicines, with innovative treatments in select areas, including CNS, pain and respiratory. We deliver high-quality generic products and medicines in nearly every therapeutic area to address unmet patient needs. We have an established presence in generics, specialty, OTC and API, building on more than a century-old legacy, with a fully integrated R&D function, strong operational base and global infrastructure and scale. We strive to act in a socially and environmentally responsible way. Headquartered in Israel, with production and research facilities around the globe, we employ 45,000 professionals, committed to improving the lives of millions of patients. Learn more at www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:
and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2017, including the sections thereof captioned "Risk Factors" and "Forward Looking Statements," and in our subsequent quarterly reports on Form 10-Q and other filings with the Securities and Exchange Commission, which are available at www.sec.gov and www.tevapharm.com. Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180912005834/en/
Teva Pharmaceutical Industries Ltd.IR ContactsKevin C. Mannix, 215-591-8912orRan Meir, 972 (3) 926-7516orPR ContactsUnited StatesElizabeth DeLuca, 267-468-4329orIsraelYonatan Beker, 972 (54) 888-5898
1 Year Teva Pharmaceutical Indu... Chart |
1 Month Teva Pharmaceutical Indu... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions